⚙️ It offers customizable support for biotech and pharma companies at every drug development stage.
📈 The aim is to enhance efficiency, save costs, and improve clinical outcomes.
🤝 Leveraging expertise from past acquisitions, this launch responds to increasing industry consolidation.
Introduction:
This article discusses the recent launch by Thermo Fisher Scientific of its expanded services in the realms of clinical research organization (CRO) and contract development and manufacturing organization (CDMO) branded as the Accelerator™ Drug Development. This suite aims to provide comprehensive support at every stage of drug development, catering to the needs of biotechnology and pharmaceutical companies.
- Thermo Fisher Scientific has launched its Accelerator™ Drug Development suite, enhancing CRO and CDMO service offerings to support drug development from preclinical to commercialization.
- The Accelerator suite is customizable and integrates existing services from previously acquired companies, PPD and Patheon, to provide a streamlined and efficient development process.
- The service aims to enhance project management, confidentiality, and cost-efficiency by providing comprehensive solutions within a single entity.
- As industry consolidation continues, Thermo Fisher ranks as a leading CDMO, competing against major players like Lonza and Catalent, while also expanding its own manufacturing capabilities.
- Thermo Fisher is implementing advanced technologies, including machine learning and artificial intelligence, to enhance drug development processes and customer service throughout various stages.
Conclusion:
The launch of Accelerator™ Drug Development by Thermo Fisher Scientific signifies a strategic move to consolidate and expand capabilities in CRO and CDMO services. This initiative is expected to streamline operations for clients and potentially enhance the efficiency and effectiveness of drug development processes, addressing a critical need within the biopharmaceutical industry as it faces increasing demand and competition.
